Abstract

BackgroundThe study of the immune microenvironment in prostate cancer (PRAD) has brought new opportunities for the current traditional treatment regimens. Therefore, our goal is to develop a universal immunodiagnostic marker to improve patient survival.MethodsBioinformatics analysis: We collected 591 samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts and evaluated the abundance and distribution of immune cell members in the PRAD expression profile matrix in the mixed cell population by CIBERSORT, ESTIMATE, single-sample gene set enrichment analysis (ssGSEA), and other methods. The target genes related to PRAD immune microenvironment and tumor mutation load were obtained by overlap analysis and verified by pan-cancer analysis. Cell experiment: The cell transfection scheme was designed, and the experiment was divided into three groups: overexpressing lactoferrin (LTF) group, empty plasmid group, and control group. After obtaining cells in each group, the gene and protein expression levels of LTF and signal transduction of signal transducer and activator of transcription 3 (STAT3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the above three groups were detected by real-time PCR and Western blot, respectively. Finally, the level of GM-CSF secretion in the three groups was detected by ELISA.ResultsMacrophages, resting mast cells, and plasma cells play an important role in PRAD immune microenvironment. In addition, high tumor mutation load [tumor mutational burden (TMB)] was positively correlated with lymph node metastasis in patients with PRAD. As the core gene of the PRAD immune microenvironment, the low expression of LTF in PRAD promotes the occurrence of immunodeficiency, PRAD, and the enrichment of the Janus kinase (JAK)/STAT3 signal pathway. Through cell experiments, it was found that the content of LTF mRNA and protein increased significantly, while the content of STAT3 and GM-CSF mRNA and protein decreased significantly in the overexpressed LTF group. The level of GM-CSF in the supernatant of cell culture was significantly decreased in the overexpression group of LTF.ConclusionThe core gene we proposed is one of the most promising biomarkers to improve the overall survival rate of PRAD and provides an important theoretical basis for the study of the mechanism of the LTF-mediated JAK/STAT3 pathway in PRAD.

Highlights

  • The study of the immune microenvironment in prostate cancer (PRAD) has brought new opportunities for the current traditional treatment regimens

  • M2 macrophage cell fractions increased in the Gene Expression Omnibus (GEO) group, while resting mast cell fractions decreased in The Cancer Genome Atlas (TCGA) and GEO groups (Figures 1A, B)

  • We found that a high immune cell infiltration score was significantly associated with poor prognosis in patients with PRAD, in which the proportion of infiltrating macrophages M0, M2 was significantly higher than that in normal tissues, while resting mast cells were lower than that in normal tissues

Read more

Summary

Introduction

The study of the immune microenvironment in prostate cancer (PRAD) has brought new opportunities for the current traditional treatment regimens. Tumor immune system-targeting therapy is considered to be an important direction in the development of anticancer drugs [3]. New immune system therapies, such as immune checkpoint blocking, cancer vaccines, and targeted antibodies, have shown significant effects in the treatment of tumors [4]. SiPuleucel-t, a personalized tumor vaccine against prostatic acid phosphatase (PAP), has become the first immune agent approved by the Food and Drug Administration (FDA) to treat CRPC. With the great advantages of bioinformatics in T-cell receptor sequencing, immune microenvironment assessment, and new antigen prediction, it has brought new ideas for current immunotherapy [6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call